Highlights Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.44 ^USD	+1.50%		+1.78%	-24.85%

Apr. 04	British billionaire Joe Lewis fined $5 million by US judge for insider trading	RE
Apr. 04	Multibillionaire Joe Lewis to face US sentencing for insider trading	RE

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

British billionaire Joe Lewis fined $5 million by US judge for insider trading	Apr. 04	RE
Multibillionaire Joe Lewis to face US sentencing for insider trading	Apr. 04	RE
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	Mar. 18	MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	Jan. 24	RE
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers	Jan. 03	CI
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q3 Revenue $10.7M	Nov. 08	MT
Tango Therapeutics Discloses Boxer Capital Acquired 1.3 Million Shares; Tango Stock Jumps in Premarket Activity	23-10-18	MT
Tango Therapeutics Receives FDA Clearance to Start the TNG348 Phase 1/2 Clinical Study	23-09-11	CI
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for Tng348, A Novel Usp1 Inhibitor for the Treatment of Brca1/2-Mutant and Other HRD+ Cancers	23-09-06	CI
Tango Therapeutics Files Prospectus for Sale of 15.5 Million Shares	23-09-01	MT
Tango Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q2 Revenue $14.6M	23-08-07	MT
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients with MTAP-Deleted Solid Tumors	23-07-10	CI
Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q1 Revenue $5.8M	23-05-09	MT
Tango Therapeutics, Inc. Presents Preclinical Data on Precision Oncology Programs At the American Association of Cancer Research 2023 Annual Meeting	23-04-18	CI
Tango Therapeutics Says US FDA Clears Investigational New Drug Application for TNG260 to Treat STK11-Mutant Cancers; Shares Rise Pre-Bell	23-04-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Highlights

Filters